GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Larimar Therapeutics Inc (STU:ZA71) » Definitions » YoY Rev. per Sh. Growth

Larimar Therapeutics (STU:ZA71) YoY Rev. per Sh. Growth : 0.00% (As of Mar. 2025)


View and export this data going back to 2020. Start your Free Trial

What is Larimar Therapeutics YoY Rev. per Sh. Growth?

YoY Rev. per Sh. Growth is the percentage change of Revenue per Share over the past twelve months. Larimar Therapeutics's YoY Rev. per Sh. Growth for the quarter that ended in Mar. 2025 was 0.00%.

Larimar Therapeutics's Revenue per Share for the three months ended in Mar. 2025 was €0.00.


Larimar Therapeutics YoY Rev. per Sh. Growth Historical Data

The historical data trend for Larimar Therapeutics's YoY Rev. per Sh. Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Larimar Therapeutics YoY Rev. per Sh. Growth Chart

Larimar Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
YoY Rev. per Sh. Growth
Get a 7-Day Free Trial - - - - -

Larimar Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
YoY Rev. per Sh. Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Larimar Therapeutics YoY Rev. per Sh. Growth Calculation

YoY Rev. per Sh. Growth is the percentage change of Revenue per Share over the past twelve months.

Larimar Therapeutics's YoY Rev. per Sh. Growth for the fiscal year that ended in Dec. 2024 is calculated as:

YoY Rev. per Sh. Growth (A: Dec. 2024 )
=(Revenue per Share (A: Dec. 2024 )-Revenue per Share (A: Dec. 2023 ))/ | Revenue per Share (A: Dec. 2023 ) |
=(0-0)/ | 0 |
=N/A %

Larimar Therapeutics's YoY Rev. per Sh. Growth for the quarter that ended in Mar. 2025 is calculated as:

YoY Rev. per Sh. Growth (Q: Mar. 2025 )
=(Revenue per Share (Q: Mar. 2025 )-Revenue per Share (Q: Mar. 2024 )) / | Revenue per Share (Q: Mar. 2024 )) |
=(0-0)/ | 0 |
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Larimar Therapeutics YoY Rev. per Sh. Growth Related Terms

Thank you for viewing the detailed overview of Larimar Therapeutics's YoY Rev. per Sh. Growth provided by GuruFocus.com. Please click on the following links to see related term pages.


Larimar Therapeutics Business Description

Traded in Other Exchanges
Address
Three Bala Plaza East, Suite 506, Bala Cynwyd, PA, USA, 19004
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.

Larimar Therapeutics Headlines

No Headlines